Lupin, Enzene Biosciences to launch cancer drug Cetuximab biosimilar in India

Lupin, Enzene Biosciences to launch cancer drug Cetuximab biosimilar in India

Lupin, an Indian pharmaceutical company, has announced a strategic collaboration with Enzene Biosciences, a subsidiary of Alkem Laboratories, to introduce Cetuximab in India. Cetuximab is the first biosimilar developed for Eli Lilly and Company’s Cetuximab, a monoclonal antibody medication used in the treatment of various types of cancer, including head and neck cancer and metastatic […]

MiraDx to enroll patients for non-tumor based microRNA clinical trial

MiraDx to enroll patients for non-tumor based microRNA clinical trial

MicroRNA clinical trial : MiraDx, a Los Angeles-based molecular genetics company, has initiated patient enrollment in collaboration with UCLA for the non-tumor based microRNA biomarker-driven clinical trial for KRAS-variant positive HPV-positive head and neck cancer patients (HNSCC). The clinical trial will randomly group 70 patients to receive the current standard of care (radiation plus cisplatin) […]

Array BioPharma’s new colorectal cancer treatment gains breakthrough therapy designation from FDA

Array BioPharma’s new colorectal cancer treatment gains breakthrough therapy designation from FDA

Array BioPharma has achieved a significant regulatory milestone as its innovative combination therapy for metastatic colorectal cancer (mCRC) has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA). The designation specifically targets the treatment regimen combining encorafenib (BRAFTOVI), binimetinib (MEKTOVI), and cetuximab for mCRC patients with the BRAFV600E mutation, following the […]